Let's hope the KoLs that have had a pretty big influence on the path Race in pursuing now via mBC have a lot bigger influence on getting oncologists to treat the relevant patients in our trial unlike our AML trial.
I can only assume targeting patients that have only been pretreated with dox has been a requirement from a BP or has a significant upside to fast tracking, funding or something else.
Ann: Race Strategic Update August 2023, page-347
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |